Adlai Nortye (ANL) Income from Continuing Operations (2024)

Adlai Nortye's (ANL) quarterly Income from Continuing Operations came in at 10000.0 in Q4 2024.

Adlai Nortye (ANL) Income from Continuing Operations (2024) Analysis & Trends

Adlai Nortye (ANL) has 1 years of Income from Continuing Operations data on file, last reported at 10000.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -37.09 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 227.36 Mn
4 NuCana 279.75 Bn 279.75 Bn - -3.68 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -26.94 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 362.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - -453.82 Mn
10 Adlai Nortye 1.27 Bn 1.26 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 -10,000.00